Future prospects for CAR-T cell therapy in AML

Saad Kenderian, MB, ChB, Mayo Clinic, Rochester, MN, shares some insights into future prospects for CAR-T cell therapy in acute myeloid leukemia (AML), highlighting the challenges of using CAR-T products in AML, and future outlooks. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.